HRQOL Data Support First-Line Lenvatinib-Pembrolizumab in Advanced Renal Cell Carcinoma
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Renal Cell Carcinoma
Robotic Partial Nephrectomy Outcomes Worse When PSMs Are Present
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
Neoadjuvant Axitinib May Enable Partial Nephrectomy in Complex Renal Tumors
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Morbid Obesity Ups Odds of Multiple Urologic Conditions
Efforts to reduce obesity may cut the prevalence of these urological conditions.
Black vs White Race Tied to Worse Survival in Renal Cell Carcinoma
While socioeconomic disparities are evident, survival differences between racial groups persist after RCC diagnosis.
ICIs May Improve mRCC Outcomes in Cytoreductive Nephrectomy Cases
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used in studies to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Treatment Advances Have Upped Survival in Metastatic Kidney Cancer
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Efficacy, Safety of Triple Combo for Advanced Kidney Cancer Probed
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
- Loading...
Loading...
Next post in IKCS 2022
Loading... 
Loading...